TRT for Men with Type 2 Diabetes: What the Research Shows

If you're a man with type 2 diabetes (T2D), the odds that you also have low testosterone are roughly 40-50%, more than double the general population. (Dandona et al., Postgrad Med 2009) And it's not a coincidence. T2D and low T are mechanistically linked: each worsens the other. Restoring testosterone to healthy levels can improve insulin sensitivity, reduce visceral fat, lower A1C, and in some cases contribute to remission of T2D.

This is the complete evidence-based guide to TRT in men with type 2 diabetes.

The T2D-low T vicious cycle

Here's what's happening:

1. Insulin resistance and visceral fat suppress testosterone. Fat tissue aromatizes testosterone to estrogen. Inflammation from metabolic syndrome disrupts the hypothalamic-pituitary-gonadal axis.
2. Low testosterone worsens insulin resistance. Testosterone helps drive glucose into muscle tissue; without enough, insulin signaling suffers.
3. Both reduce muscle mass. Low T + high glucose = accelerated sarcopenia.
4. Less muscle = less glucose disposal capacity = worse insulin resistance.
5. And the cycle continues.

Treating T2D without addressing low testosterone in hypogonadal men leaves a major lever pulled against you.

What the research shows

The T4DM trial (2021)

The Testosterone for the Prevention of Type 2 Diabetes Mellitus (T4DM) trial was a landmark Australian study of 1,007 men with prediabetes or newly diagnosed T2D. (Wittert et al., Lancet Diabetes Endocrinol 2021) Over 2 years, men on TRT + lifestyle showed:

• Lower progression to T2D (34% reduction)
• Higher rates of T2D remission
• Improved fasting glucose and insulin
• Better body composition (lean mass up, fat mass down)
• No increase in adverse events vs. placebo

The TRAVERSE trial (2023)

The largest TRT safety trial ever, over 5,000 men with cardiovascular risk factors. (Lincoff et al., N Engl J Med 2023) Key findings relevant to T2D:

• No increased cardiovascular risk from TRT
• Improvements in HbA1c and insulin resistance markers
• Improved lipid profiles

Additional research

• Meta-analyses of men with both low testosterone and T2D report reductions in A1C, though the size varies by analysis — roughly 0.9% in one 2014 review and about 0.3% in a 2023 systematic review, whose insulin-resistance result did not reach statistical significance (Cai et al., Asian J Androl 2014)
• Changes in body composition, including visceral fat, are reported across several studies
• Reduced fatigue, improved exercise capacity, better adherence to diabetes care

Who is a candidate?

TRT in T2D is generally appropriate for:

• Men with T2D + total testosterone below 300 ng/dL
• Men with T2D + symptoms of hypogonadism even at "low-normal" T levels (300-400 ng/dL)
• Men with prediabetes + low T
• Men with metabolic syndrome + symptomatic low T

The threshold for treatment may be lower when T2D is present, because the metabolic benefits compound with hormone optimization.

Considerations specific to T2D patients

Monitor hematocrit closely

TRT raises red blood cell production. Men with T2D who smoke, have sleep apnea, or are obese already have elevated baseline hematocrit, TRT can push it higher. Monitor every 3 months initially.

Sleep apnea screening

T2D + obesity = high sleep apnea prevalence. Untreated sleep apnea is a major driver of low T. Sleep study often warranted before starting TRT.

Blood pressure monitoring

TRT can transiently raise BP in some men. Baseline and periodic monitoring important in this population.

Blood sugar monitoring

As insulin sensitivity improves, diabetes medications may need to be reduced to avoid hypoglycemia. Coordinate with your diabetes provider.

TRT + GLP-1: a powerful combination

Many men with T2D + low T benefit significantly from combining TRT with a GLP-1 medication like semaglutide or tirzepatide. The synergy:

• GLP-1 drives weight loss and directly improves insulin sensitivity
• TRT restores muscle protein synthesis + preserves muscle during GLP-1 weight loss + further improves insulin sensitivity
• Together: metabolic improvements are often dramatic, rapid A1C reduction, visceral fat loss, muscle preservation, better energy

This combination is increasingly the protocol for T2D men with hypogonadism. See our GLP-1 comparison.

Expected outcomes on TRT in T2D

• Month 1-2: Energy, mood, libido improve
• Month 3-4: Body composition begins shifting; A1C starts trending down
• Month 6: Measurable improvements in labs, insulin, A1C, visceral fat
• Month 12: Full metabolic benefits visible; may be able to reduce diabetes medications

What TRT does NOT do

• It doesn't replace diabetes medications
• It doesn't cure T2D
• It doesn't eliminate the need for diet, exercise, and weight management
• It doesn't work equally well in every patient, about 70-80% of hypogonadal T2D men see meaningful improvements

The bottom line

If you're a man with type 2 diabetes and you haven't had your testosterone checked, that's a gap. Nearly half of diabetic men have clinically low testosterone, and in those men, TRT measurably improves glucose control, body composition, and cardiovascular markers. Combined with modern GLP-1 therapy and lifestyle fundamentals, it's a genuine game-changer for metabolic health.